Nektar Therapeutics, a clinical-stage biotechnology company specializing in immunotherapy, has successfully closed a public offering, raising $115 million. The company sold 4,893,618 shares of its common stock, which includes an additional 638,298 shares sold following the full exercise of the underwriters' option to purchase extra shares. The shares were sold at a price of $23.50 each. The proceeds from this offering will be used for general corporate purposes, including research, clinical development, and manufacturing costs to advance Nektar's drug candidates. Jefferies and Piper Sandler served as joint bookrunning managers for the offering, with BTIG, LLC and H.C. Wainwright & Co. also participating in management roles.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.